Earnings Call · Q2 FY2021·2021-08-03

Q2 21EPS -28.57%·Rev n/aQ1 21EPS -33.33%·Rev n/aQ4 20EPS -39.47%·Rev n/aQ3 20EPS +11.32%·Rev n/a⚠ consensus missing

Ultragenyx Pharmaceutical Inc. RARE

Joshua Higa — Director of Investor Relations

Emil Kakkis — Chief Executive Officer

Erik Harris — Chief Commercial Officer

Camille Bedrosian — Vice President, Clinical Development

+3.6%1d on move date+2.8% vs SPY3d+11.7%5d+11.3%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more RARE calls or request research access.

More RARE calls Browse calls Request research access